Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High – Still a Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high on Thursday . The company traded as high as $117.88 and last traded at $113.70, with a volume of 793226 shares traded. The stock had previously closed at $115.54.

Analysts Set New Price Targets

DNTH has been the topic of several analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Stock Performance

The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -27.40 and a beta of 1.22. The company has a 50-day moving average price of $99.51 and a 200-day moving average price of $84.41.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Marino Garcia sold 166,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the sale, the chief executive officer owned 65,292 shares in the company, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 287,084 shares of company stock valued at $29,615,923 over the last three months. 3.02% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $401,990,000. Wellington Management Group LLP lifted its holdings in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP boosted its position in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. State Street Corp boosted its position in shares of Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares during the period. Finally, Polar Capital Holdings Plc purchased a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $29,434,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.